Nahdi Medical Company

Nahdi Medical Company

TTADAWUL:4164
85.40
SAR
-2.20
(-2.51%)
6.66EPS
13.97P/E
12.09BMarket Cap
Nov 04Next Earn
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
62.05
66.28
67.03
72.66
78.56
81.43
Basic EPS, GAAP
6.25
6.83
6.87
6.31
6.39
6.66
Free Cash Flow per Basic Share
7.9
10.71
7.17
8.51
5.51
4.3
Dividend per Share
9.69
2.31
5.5
5.5
5.6
0.01
Book Value per Share
12.34
17.26
18.94
19.89
21.1
19.32
Tangible Book Value per Share
12
16.89
18.55
19.37
20.58
18.81
Basic Weighted Avg Shares
130
130
130
130
130
130
Sales/Revenue/Turnover
8,066
8,616
8,714
9,446
10,213
10,586
Operating Margin (%)
10.84
11.58
10.99
9.16
8.97
9.11
Depreciation Expense
572
597
618
703
795
807
Net Income, GAAP
813
888
893
821
831
865
Effective Tax Rate (%)
5.22
5.34
5.47
1.66
1.79
2.62
Profit Margin (%)
10.07
10.3
10.24
8.69
8.13
8.17
Working Capital
514
1,055
1,117
1,088
1,151
717
LT Debt
992
792
871
1,146
1,363
1,340
Total Equity
1,604
2,243
2,463
2,586
2,744
2,512
Return on Invested Capital (%)
- -
28.9
25.04
21.64
20.77
22.56
Return on Capital (%)
- -
29.36
26.68
23.04
21.22
22.82
Return on Common Equity (%)
- -
46.16
37.93
32.51
31.17
34.88

Capital Structure

SAR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
420
388
417
LT Borrowings
- -
- -
- -
LT Finance Leases
1,363
1,382
1,340
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
130
130
130
Market Capitalization
12,350
13,663
12,090

Working Capital

SAR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,299
4,037
3,275
Cash, Cash Equivalents & STI
554
1,216
511
Accounts Receivable, Net
261
279
310
Inventories
2,278
2,323
2,161
Total Current Liabilities
2,148
3,006
2,558
Payables & Accruals
- -
- -
- -
ST Debt
420
388
417
Deferred Revenue
- -
- -
- -

Growth Rates

SAR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
6.09%
Free Cash Flow
- -
- -
-35.3%
Net Income, GAAP
- -
- -
1.22%
Sales/Revenue/Turnover
- -
- -
8.12%
Total Cash Common Dividend
- -
- -
1.82%

Quarterly Revenue

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,257
2,473
2,353
2,363
9,446
2025
2,635
2,528
- -
2,589
10,213
2026
2,794
2,674
- -
- -
- -

Quarterly Earnings Per Share

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.79
1.91
1.4
1.21
6.31
2025
1.96
1.83
- -
1.35
6.39
2026
1.81
1.66
- -
- -
- -

Quarterly Dividends Per Share

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.99
0.01
2.5
- -
5.5
2025
2.99
0.01
- -
- -
5.6
2026
- -
- -
- -
- -
- -

Company Description

CEO
Yasser Ghulam Abdulaziz Joharji
Full Time Employees
5,169
Sector
Distribution services
Industry
Medical distributors
Address
7296 King Abdulaziz Road Jeddah MC Saudi Arabia 23715-3985
IPO Date
Mar 22, 2022
Website
nahdi.sa
Business
Nahdi Medical Company is a Saudi joint-stock company specializing in pharmaceutical retail and healthcare services. The company operates an extensive network of retail pharmacies, including more than 1,200 outlets across Saudi Arabia and one in Dubai, United Arab Emirates. Nahdi offers a comprehensive range of products and services including pharmaceutical and health products across categories such as health and wellness, mom and baby, beauty, everyday essentials, medical devices, cosmetics, special and health food, and medical equipment. Additionally, Nahdi operates Nahdi Care Clinics providing primary healthcare services such as dental care, dermatology, pediatrics, cardiology, telemedicine services, labs, and home healthcare. The company complements its physical presence with digital capabilities through the Nahdi Online e-commerce platform and the E-Pharmacist service for virtual pharmacist consultations. Founded in 1986 and headquartered in Jeddah, Saudi Arabia, Nahdi Medical Company serves approximately 97 percent of the population within Saudi Arabia, supported by over 10,000 employees. The company's strategic initiatives include a strong digital transformation focus with investments in cloud computing, omnichannel retailing, and data analytics to enhance customer experience and supply chain robustness. In recent years, Nahdi has expanded its healthcare footprint by adding new NahdiCare polyclinics in multiple Saudi cities such as Jeddah, Makkah, Taif, Madina, Yanbu, Najran, and Khamis Mushait, exceeding its 2026 expansion targets ahead of schedule. The company has launched private label and differentiated brands contributing significantly to local content under the Saudi Vision 2030 "Made in Saudi" program. Nahdi also formed a key partnership with Emerge, a Masdar and EDF Group joint venture, to install a rooftop solar power system for its distribution center as part of its sustainability efforts aligned with the Saudi Green Initiative. In 2024, Nahdi Medical Company achieved 8.4% year-on-year revenue growth, reflecting strong market performance despite competitive conditions. The company launched a revamped website and mobile app featuring an AI-enhanced interface to improve digital engagement and integrate its omnichannel services further. Nahdi continues to focus on strategic growth by strengthening its retail presence, advancing its digital health services, and expanding geographically within the Kingdom and the UAE, solidifying its position as a leading national healthcare provider. These developments underscore Nahdi's commitment to innovation, guest-centric care, and sustainable business practices in alignment with Saudi Arabia's Vision 2030 objectives.